Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting ( Commission. You arecautioned not to p...)

(Date:7/22/2008)...SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire/ ...t it has completed patient enrollment,in its Phase...bility and,ammonia scavenging effects of HPN-100 (...henylbutyrate) in patients with urea cycle disorde...esults in the fourth quarter,of this year., (Logo...

(Date:7/22/2008)... Developed and Validated by Columbia University Me...Proprietary MicroRNA Technology, The Test Differ... Lung Cancer (NSCLC), Classifying Squamous-Cell C... Percent and Specificity of 90 Percent,This is the...s, Sensitivity as Biomarkers for Accurate...

(Date:7/22/2008)...SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-Firs...nnounced it has successfully completed the,enrollm...olled hypertension,in two clinical pharmacology st...y announced timelines. These trials are designed t..., in comparison to ibuprofen and,naproxen, using t...

(Date:7/22/2008)...Pilot Study Suggests That Ekkyo,s New Approach of ...ally Improve Scar Healing Physiology, MARSEILLES,...nown as,Heatwave Technology) a photomedicine compa...ems for skin scar prevention and reduction, announ...in Lasers in Surgery and Medicine*,reporting the r...

Breaking Medicine Technology:Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2 Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3 First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2 First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3 First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4 First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5 NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2 NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3 Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2 Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3 Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 1 Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 2 Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 3 Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 4 JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 1 JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 2 JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 3 JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 4 ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 1 ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 2 ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 3 Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 1 Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 2 Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 3

[0] Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders [1] First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval [0] NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients [0] Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"

...Maintained Stability,Significantly Longer than Pla...Comparable with Placebo , MARIETTA, Ga. and COLLEG..., Inc., Wyeth Pharmaceuticals, a division of Wyeth...tudy results on,bifeprunox, an investigational tre...enia, today at the 2007 annual meeting of,the Amer...

...ire-FirstCall/ -- Forest,Laboratories, Inc. and Cy...inary top-line results from a 1,196 patient random...d pivotal Phase III,study demonstrate statisticall...s a treatment of fibromyalgia syndrome. At this ti...tial top-line,results and further analyses will be...

Other Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2 New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3 New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4 New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5 Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2 Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3 Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4 Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5 Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6

New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome

(Date:7/25/2008)... jobs created in the medical field slowed in June,...d of slowdown: they laid off fewer people in June ... Seattle, WA (PRWEB) July 25, 2008 -- Though the ... in June overall, pharmaceutical companies reporte...to the ears of sales representatives: fewer layoff...

(Date:7/25/2008)... J. Reilly, Joins Aethon Team, PITTSBURGH, July 2...com ), the leading developer of mobile robotics fo... that Robert J. Reilly has,joined the company as S... Reilly, who was most recently Vice President -- G...y Pharmacy Division, brings more than 30,years of ...

(Date:7/25/2008)...se immune system changes , , FRIDAY, Jul...g gastroesophageal reflux disease (GERD) and asthm...enter researchers. , An association between the...since then studies have shown that between 50 perc...nce GERD symptoms. But the actual link between GER...

(Date:7/25/2008)... Association (DIA) and the Food and Drug Administr... (CPI) on the Move: Complexities and Challenges (S...th Transporter Workshop (October 2-3; North Bethes...RWEB) July 25, 2005-- The http://www.diahome.org/...d and Drug Administration (FDA) will host the htt...

Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2 Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3 Health News:Aethon, Inc. Names New Chief Financial Officer 2 Health News:People With GERD More Likely to Develop Asthma 2 Health News:DIA And FDA To Host Two Important Critical Path Workshops 2 Health News:DIA And FDA To Host Two Important Critical Path Workshops 3

[0] The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health [0] Aethon, Inc. Names New Chief Financial Officer [0] People With GERD More Likely to Develop Asthma [0] DIA And FDA To Host Two Important Critical Path Workshops

...enge releases a dose of nicotine and is one of the...uit smoking.// The federal government has announc...nada. The lozenges are to join nicotine patches, g...er the counter. This decision was taken because th...

...re Commission today came down heavily on senior ma...were responsible for the spread of a lethal bug// ...gets above infection control. A couple of outbrea...pital resulted in 33 deaths far more than the 12 o...

...e-up of community health care could cause a change...e been made to merge the roles of community health...t nurses into one community health job. This could...ss Scotland. These were the plans that were outli...

...shington residents have taken ill after eating raw...t of Health has reported. The Health department ha...oid eating raw shellfish. Oysters that are prope...ut raw oysters may be prone to bacteria that is fo...

Other Medicine News:Health News:"Serious Failings" Led To Spread Of Lethal Hospital Bug 2

Is Nicotine Lozenge A Safe Smoking Cessation Product?"Serious Failings" Led To Spread Of Lethal Hospital Bug Community Health Shake-up Spells Trouble for Nurses A warning against consumption of raw oyster

Packed conveniently in plastic-wrapped racks of 96 tips, Sterilized Diamond- Tips are ready to useno need to autoclave. Sterilized Diamond Tips are irradiated by gamma-rays for more efficient sterili

Designed for applications that demand the utmost in biological purity, individually packed Finntip BioCon tips are endotoxin-free, DNA-free, DNase-free and RNase-free. Finntip BioCon tips are guaran

Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been

Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting.

Medicine Products:

Tipack (Sterilized) D10 Finntip BioCon Finntip 10 (Sterile)ART 300 Multi-Channel

( Commission. You arecautioned not to p...)Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting,Health